Skip to main content
. 2023 Jan 24;15(3):710. doi: 10.3390/cancers15030710

Table 3.

New treatments perspectives.

Preclinical Stage
Drug Targets Therapies Thyroid Cancer Model Experimentation Type Effectiveness criteria Ref
ARAF, BRAF, CRAF TAK-632
vs. vemurafenib		 3 ATC BRAFV600E cell lines - Quantification of MAPK pathway inhibition
- Proliferation assay		 TAK-632 > vemurafenib:
On MAPK inhibition
On GI50 and IC50		 [56]
ARAF, BRAF, CRAF LY3009120
vs. vemurafenib		 - 3 PTC BRAFV600E cell lines
- Mouse xenograft model		 - Viability assay
- Apoptosis assay
- Cytotoxic assay
- In vivo tumor growth
  • 1)

    LY3009120 overcame vemurafenib resistance due to BRAF-CRAF dimerization

  • 2)

    LY3009120 > vemurafenib:

On cell viability, toxicity and apoptosis
On tumor growth inhibition in vivo		 [58]
RAF + ERK1/2 Dabrafenib + SCH772984 - 5 BRAFV600E cell lines (ATC + DTC)
- Mouse xenograft model		 - Quantification of MAPK pathway inhibition
- Viability assay
- Apoptosis assay
- In vivo tumor growth		 Dabrafenib + SCH772984 avoid MAPK reactivation observed with dabrafenib alone
  • 1)

    Dabrafenib + SCH772984 > Dabrafenib or SCH772984 alone:

On cell viability and apoptosis
On tumor growth inhibition in vivo		 [59]

Abbreviations: vs., versus.